Skip to main content
SpringerLink
Log in

Role of ischemia-modified albumin in estimating the extent and scope of cardiac ischemia in patients with ST elevation myocardial infarction

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

Ischemia-modified albumin (IMA) is a laboratory biomarker of cardiac ischemia. Our study aims to determine whether IMA can estimate or represent to any degree the extent of myocardial ischemia. We expect that the higher the marker of cardiac necrosis (maximum value after serial measurements) the greater the preceding cardiac ischemia, indicated by IMA in patients diagnosed with STEMI prior to direct percutaneous coronary intervention (PCI). We studied 216 patients indicated for direct PCI with a diagnosis of ST elevation myocardial infarction. Biochemical analysis of IMA was carried out using the albumin cobalt binding (ACB®) test. We also obtained relevant values for markers of myocardial necrosis (CK, CK-MB, cTnT). In all patients, there was an increased level of IMA prior to the procedure (116 ± 16.9 kU/l); also raised were levels of CK (17.32 μkat/l), CK-MB (4.85 μkat/l) and cTnT (2.97 μg/l) taken as the maximum values obtained after serial measurements at 12, 18, and 24 h after the procedure. We observed that there was no significant association between increase in IMA and cTnT (R 2 = 0.0068, p = 0.483). This was also the case for CK-MB (R 2 = 0.0011, p = 0.637). IMA does not estimate the extent of ischemia in patients with ST elevation myocardial infarction. However, its absence can be used qualitatively to rule out cardiac ischemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bar-Or D, Lau E, Rao N, Bampos N, Winkler JV, Curtis CG (1999) Reduction in the cobalt binding capacity of human albumin with myocardial ischemia. Ann Energ Med 43:56

    Article  Google Scholar 

  2. Wu AH, Crosby P, Fagen G (2003) Ischemia modified albumin, free fatty acids, whole blood choline, B-type natriuretic peptide, glycogen phosphorylase BB, and cardiac troponins. In: Wu AHB (ed) Cardiac markers. Humana Press, Totowa, pp 259–278

  3. Quiles J, Roy D, Gaze D, Garrido IP, Avanzas P, Sinha M, Kaski JC (2003) Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol 92:322–324

    Article  PubMed  CAS  Google Scholar 

  4. Roy D, Quiles J, Sharma R, Sinha M, Avanzas P, Gaze D, Kaski JC (2004) Ischemia modified albumin concentrations in patients with peripheral vascular disease and exercise induced skeletal muscle ischemia. Clin Chem 50:1656–1660

    Article  PubMed  CAS  Google Scholar 

  5. Zapico-Muñiz E, Santaló-Bel M, Mercé-Muntañola J, Montiel JA, Martínez-Rubio A, Ordóñez-LIanos J (2004) Ischemia-modified albumin during skeletal muscle ischemia. Clin Chem 5:1063–1065

    Article  Google Scholar 

  6. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF (2006) Role of reactive oxygen species on the formation of the novel diagnostic marker ischemia modified albumin. Heart 92:113–114

    Article  PubMed  CAS  Google Scholar 

  7. Kösem A, Haklıgör A, Yücel D (2008) Effects of calcium (II), magnesium (II), copper (II) and iron (II) ions on ischemia modified albumin. Turk J Biochem 33:31–34

    Google Scholar 

  8. Bar-Or D, Rael LT, Bar-Or R, Slone DS, Mains CW, Rao NK, Curtis CG (2008) The cobalt-albumin binding assay: insights into its mode of action. Clin Chim Acta 387:1–2

    Article  Google Scholar 

  9. Christenson RH, Duh SH, Sanhai WR, Wu Ah, Holtman V, Painter P, Branham E, Apple FS, Murakami M, Morris DL (2001) Characteristics of an albumin cobalt binding test for the assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 47:464–470

    PubMed  CAS  Google Scholar 

  10. Gidenne S, Ceppa F, Fontan E, Perrier F, Burnat P (2004) Analytical performance of the albumin cobalt binding (ACB) test on the Cobas MIRA® Plus analyzer. Clin Chem Lab Med 42:455–461

    Article  PubMed  CAS  Google Scholar 

  11. Garrido IP, Roy D, Calvino R, Vazquez-Rodriguez JM, Aldama G, Cosin-Sales J, Quiles J, Gaze DC, Kaski JC (2004) Comparison of ischemia-modified albumin levels in patients undergoing percutaneous coronary intervention for unstable angina pectoris with versus without collaterals. Am J Cardiol 93:88–90

    Article  PubMed  CAS  Google Scholar 

  12. Lippi G, Montagnana M, Salvagno GL, Guidi GC (2007) Standardization of ischemia modified albumin testing: adjustment for serum albumin. Clin Chem Lab Med 45:261–262

    Article  PubMed  CAS  Google Scholar 

  13. Kiyici A, Mehmetoglu I, Karaoglan H, Atalay H, Solak Y, Turk S (2010) Ischemia modified albumin levels in patients with end-stage renal disease patients on hemodialysis. Does albumin analysis method affect albumin-adjusted ischemia-modified albumin levels? J Clin Lab Anal 24:273–277

    Article  PubMed  CAS  Google Scholar 

  14. Beetham R, Monk C, Keating L, Benger JR, Kendall J (2006) Effects of storage at −20 degrees C on ischemia-modified albumin results. Ann Clin Biochem 43:500–502

    Article  PubMed  CAS  Google Scholar 

  15. Panteghini M, Cuccia C, Bonetti G, Giubbini R, Pagani F, Bonini E (2002) Single-point cardiac troponin T at coronary care unit discharge after myocardial infarction correlates with infarct size and ejection fraction. Clin Chem 48:1432–1436

    PubMed  CAS  Google Scholar 

  16. Al-Saady NM, Camm AJ (1998) New soluble markers for assessment of infarct size. Early detection by novel biochemical markers. Kluwer, Dordrecht, pp 137–148

    Google Scholar 

  17. Grande P, Fischer Hansen B, Christiansen C, Naestoft J (1982) Estimation of acute myocardial infarct size in man by serum CK-MB measurements. Circulation 65:756–764

    Article  PubMed  CAS  Google Scholar 

  18. Grande P, Christiansen C, Alstrup K (1983) Comparison of ASAT, CK, CK-MB, and LD for the estimation of acute myocardial infarct size in man. Clin Chim Acta 128:329–335

    Article  PubMed  CAS  Google Scholar 

  19. Berry C, Balachandran KP, L′Allier PL, Lespérance J, Bonan R, Oldroyd KG (2007) Importance of collateral circulation in coronary heart disease. Eur Heart J 38:278–291

    Article  Google Scholar 

  20. Camm JA, Luscher TF, Serruys PW (2006) The ESC textbook of cardiovascular Medicine. Blackwell Publishing, Oxford, pp 317–318

    Google Scholar 

  21. Hjortsoj S, Dethlefsen C, Kristensen SR, RavKilde J (2009) Kinetics of ischemia modified albumin during ongoing severe myocardial ischemia. Clin Chim Acta 403:114–120

    Article  Google Scholar 

  22. Hjortshoj S, Dethlefsen C, Kristensen SR, Ravkilde J (2010) Determinants of the release pattern of ischemia modified albumin in acute ST elevation myocardial infarction treated with primary PCI. Scand J Clin Lab Invest 70:244–251

    Article  PubMed  Google Scholar 

  23. Feng Y, Shen C, Ma G, Wang J, Chen Z, Dai Q, Zhi H, Yang C, Fu Q, Shang G, Guan Y (2010) Prolonged pain to hospital time is associated with increased plasma advanced oxidation protein products and poor prognosis in patients with percutaneous coronary intervention for ST-elevation myocardial infarction. Heart Vessels 25:374–378

    Article  PubMed  CAS  Google Scholar 

  24. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M, Samimi-Fard S, Kaski FC (2008) Relation of ischemia modified albumin levels and left ventricular systolic function in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Clin Chim Acta 388:196–199

    Article  PubMed  CAS  Google Scholar 

  25. Dominguez-Rodriguez A, Abreu-Gonzalez P, de la Rosa A, Ferrer J, Garcia M (2005) Role of endogenous interleukin-10 production and lipid peroxidation in patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty, interleukin-10 and primary angioplasty. Int J Cardiol 99:77–81

    Article  PubMed  Google Scholar 

  26. Roy D, Kaski JC (2007) Ischemia-modified albumin: the importance of oxidative stress. J Am Coll Cardiol 49:2375–2376

    Article  PubMed  Google Scholar 

  27. Consuegra-Sanchez L, Bouzas-Mosquera A (2008) Ischemia-modified albumin predicts short-term outcome and 1-year mortality in patients attending the emergency department for acute ischemic chest pain. Heart Vessels 23:174–180

    Article  PubMed  Google Scholar 

  28. Dusek J, Stasek J, Tichy M, Bis J, Gregor J, Vojacek J, Masin V, Polansky P, Brtko M, Cernohorsky D (2006) Prognostic significance of ischemia modified albumin after cutaneous coronary intervention. Clin Chim Acta 367:77–80

    Article  PubMed  CAS  Google Scholar 

  29. Akdemir R, Katakurt O, Klic H, Yesilay AB, Dogan M, Cagirci G, Acikel S, Akdemir N (2010) Effect of reperfusion therapy on index of myocardial performance in acute myocardial infarction: thrombolytics versus primary angioplasty. Heart Vessels 25:87–91

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This research project was co-sponsored by various grant providers to which we are indebted. This included grants from ROCHE––24180, the Ministry of Health in the Czech Rep (IGA NR/9174-3), and MZO 00179906.

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, University Hospital Hradec Králové, Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic, Sokolská 581, 500 05, Hradec Králové, Czech Republic

    James Chek, Jaroslav Dusek, Josef Stasek, Jan Vojacek, Josef Bis & Tomas Tomko

  2. Department of Biochemistry, University Hospital Hradec Králové, Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic, Hradec Králové, Czech Republic

    Martina Ulrychova & Milos Tichy

  3. Department of Medical Biophysics and Biostatistics, Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic, Hradec Králové, Czech Republic

    Josef Bukac

Authors
  1. James Chek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaroslav Dusek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Josef Stasek
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jan Vojacek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Josef Bis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martina Ulrychova
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Milos Tichy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tomas Tomko
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Josef Bukac
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James Chek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chek, J., Dusek, J., Stasek, J. et al. Role of ischemia-modified albumin in estimating the extent and scope of cardiac ischemia in patients with ST elevation myocardial infarction. Heart Vessels 26, 622–627 (2011). https://doi.org/10.1007/s00380-010-0114-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-010-0114-0

Keywords

Search

Navigation